Idexx Laboratories

Current directors and officers who also hold a role at another S&P 500 company.

• Bruce L. ClaflinCIEN · Director
• Jonathan Jay MazelskyPODD · Director
• Joseph L. HooleyAPTV · Director
• Sam SamadDGX · CFO
• Sophie Vandebroek VRVTY · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Mar 26, 2026

   On March 24, 2026, IDEXX Laboratories, Inc. (“IDEXX”) and Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, mutually agreed that Dr. Hunt will cease serving in her current role effective on April 13, 2026 (the “Separation Date”) and will continue to provide advisory services on an as-needed basis until July 13, 2026 (the “Final Employment Date”). IDEXX and Dr. Hunt entered into a separation letter agreement (the “Separation Agreement”) to memorialize the terms of Dr. Hunt’s advisory role and subsequent departure. Pursuant to the Separation Agreement, IDEXX will pay to Dr. Hunt separation benefits in the form of (i) salary continuation for 104 weeks following the Separation Date, in the aggregate amount of $1,230,000; (ii) Dr.

   Read the 8-K filing
2. Feb 13, 2026

   (b) On February 13, 2026, Ms. M. Anne Szostak provided IDEXX Laboratories, Inc. (the “Company”) notice of her intention to retire from the Board of Directors (the “Board”) effective immediately following the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) to be held on May 12, 2026. Ms. Szostak’s decision to retire from the Board does not arise from any disagreement with the Company or the Board on any matter relating to the Company’s operations, policies, practices or otherwise. The Company thanks Ms. Szostak for her extraordinary service, contributions and leadership during her tenure as a member of the Board since 2012. In accordance with the Company’s amended and restated by-laws, the Board reduced the size of Class III, effective upon Ms.

   Read the 8-K filing
3. Jan 13, 2026

   CEO Transition. On January 11, 2026, Jonathan (Jay) Mazelsky notified IDEXX Laboratories, Inc. (the “Company” or “IDEXX”) of his intent to step down as the Company’s President and Chief Executive Officer effective as of May 12, 2026 (the “Transition Date”) and retire from the Company and the Company’s Board of the Directors (the “Board”) immediately following the Company’s annual meeting of shareholders in May 2027 (the “Retirement Date”). On January 13, 2026, the Company announced that effective as of the Transition Date Mr. Mazelsky will transition to the role of Executive Chair of the Board and Michael (Mike) Erickson, PhD, will assume the role of President and Chief Executive Officer of the Company and join the Board as a Class II Director. In his capacity as President and Chief Executive Officer, Dr. Erickson will serve as the Company’s principal executive officer. Mr.

   Read the 8-K filing
4. Oct 7, 2025

   Election of New Director. Effective October 6, 2025, the board of directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”) elected Karen Peacock as an independent Class I Director and appointed her as a member of its Compensation and Talent Committee and Finance Committee. To effect Ms. Peacock’s election as a Class I Director, the Board increased the number of Directors constituting the Board from ten to eleven and the number of Class I Directors from three to four. It is expected that Ms. Peacock will stand for election by stockholders as a Class I Director at the Company’s 2027 annual meeting of stockholders. There are no related person transactions (or proposed related person transactions) with respect to Ms. Peacock reportable under

   Read the 8-K filing
5. Jul 10, 2025

   Election of New Director. Effective July 10, 2025, the board of directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”) elected Joseph L. (Jay) Hooley as an independent Class III Director and appointed him as a member of its Audit Committee and Governance and Corporate Responsibility Committee. To effect Mr. Hooley’s election as a Class III Director, the Board increased the number of Directors constituting the Board from nine to ten and the number of Class III Directors from three to four. It is expected that Mr. Hooley will stand for election by stockholders as a Class III Director at the Company’s 2028 annual meeting of stockholders. There are no related person transactions (or proposed related person transactions) with respect to Mr. Hooley reportable under

   Read the 8-K filing
6. Feb 14, 2025

   (b) On February 13, 2025, Dr. Asha Collins resigned from the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), effective immediately. Dr. Collins’s decision to resign was not the result of any disagreement with the Company on any matters relating to the Company’s operations, policies or practices. The Company and Board thank Dr. Collins for her service during her tenure as a member of the Board and wishes her well in her future endeavors. In connection with Dr. Collins’s resignation, the size of the Board was reduced from ten to nine directors. 1

   Read the 8-K filing
7. Dec 12, 2024

   Adoption of Nonqualified Deferred Compensation Plan On December 6, 2024, the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), upon the recommendation of the Compensation and Talent Committee of the Board (the “Committee”), approved and adopted the IDEXX Deferred Compensation Plan (the “Plan”). The Plan constitutes an unfunded, nonqualified deferred compensation plan that allows a select group of management and highly compensated employees or independent contractors (the “Participants”), to voluntarily defer compensation in a manner intended to comply with Section 409A of the Internal Revenue Code of 1986, as amended.

   Read the 8-K filing
8. Nov 21, 2024

   On November 20, 2024, Brian P. McKeon, Executive Vice President, Chief Financial Officer and Treasurer of IDEXX Laboratories, Inc. (the “Company” or “IDEXX”) notified the Company that he will retire from IDEXX effective June 1, 2025. Mr. McKeon has served as the Company’s Executive Vice President, Chief Financial Officer and Treasurer since January 2014 and was previously a member of the Company’s Board of Directors (the “Board”) from July 2003 through December 2013. Mr. McKeon will cease serving as the Company’s Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer, effective March 1, 2025, and will serve as Executive Vice President and Special Advisor to the Company from March 1, 2025, until his retirement on June 1, 2025, to help ensure a smooth and seamless transition. Mr.

   Read the 8-K filing
9. Nov 12, 2024

   (b)           On November 8, 2024, Jonathan W. Ayers, a member of the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), resigned from the Board and its finance committee, effective November 8, 2024. A copy of Mr. Ayers’s resignation letter is included as Exhibit 99.1 to this Current Report on Form 8-K. Mr. Ayers’s decision to resign was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Ayers served as the Company’s Chairman of the Board, President and Chief Executive Officer from 2002 through 2019 and as a non-employee director from 2019 until November 8, 2024. The Company and Board thank Mr. Ayers for his more than two decades of service and leadership at the Company and are grateful for his many valuable contributions during his long tenure. In connection with Mr.

   Read the 8-K filing
10. May 10, 2024

    Consulting Agreement with James F. Polewaczyk Effective May 7, 2024, IDEXX Laboratories, Inc. (the “Company”) and James F. Polewaczyk, entered into a Consulting Agreement (the “Consulting Agreement”). Mr. Polewaczyk was an Executive Vice President of the Company who retired effective April 1, 2024. Under this arrangement, Mr. Polewaczyk will provide coaching and professional development support to selected Company employees and will receive compensation of $25,000 per month (the “Consulting Fees”). The Consulting Agreement has an initial term of one year and may be terminated by either party by providing 60 days’ written notice to the other party. The Consulting Agreement may be renewed for a one-year term upon mutual agreement by the parities. The Consulting Agreement, the terms of which are incorporated herein by reference, is attached hereto as Exhibit 10.1.

    Read the 8-K filing
11. Dec 7, 2023

    On December 5, 2023, James F. Polewaczyk, Executive Vice President and Chief Commercial Officer of IDEXX Laboratories, Inc. (the “Company”), notified the Company of his intent to retire after more than 17 years of dedicated leadership and service, effective April 1, 2024.

    Read the 8-K filing
12. Jul 12, 2023

    Election of New Director. On July 11, 2023 the board of directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”) elected Irene Chang Britt as an independent Class I Director and appointed her as an independent member of its Audit Committee and Compensation and Talent Committee, effective as of that date. To effect Ms. Chang Britt’s election as a Class I Director, the Board increased the number of Directors constituting the Board from ten to eleven and the number of Class I Directors from three to four. It is expected that Ms. Chang Britt will stand for election by stockholders as a Class I Director at the Company’s 2024 annual meeting of stockholders. There are no related person transactions (or currently proposed related person transactions) with respect to Ms. Chang Britt reportable under

    Read the 8-K filing
13. Feb 10, 2021

    Director or officer change (Item 5.02). Open the filing for details.

    Read the 8-K filing
14. Nov 12, 2020

    Election of New Director. Effective November 11, 2020, the board of directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”) elected Dr. Asha S. Collins as an independent Class I Director and appointed her as a member of its Nominating and Governance Committee. To effect Dr. Collins’s election as a Class I Director, the Board increased the number of Directors constituting the Board from ten to eleven and the number of Class I Directors from three to four. It is expected that Dr. Collins will stand for election by stockholders as a Class I Director at the Company’s 2021 annual meeting of stockholders. There are no related person transactions (or proposed related person transactions) with respect to Dr. Collins reportable under

    Read the 8-K filing
15. Oct 24, 2019

    Recent Actions On October 23, 2019, IDEXX Laboratories, Inc. (the “ Company ”) and Jonathan W. Ayers, the Company’s Chairman of the Board and former President and Chief Executive Officer, mutually agreed that Mr. Ayers, who has been on medical leave since June 28, 2019, will cease to be employed by the Company as of November 1, 2019 (the “ Transition Date ”) and transition to the role of external Senior Advisor to the Company. Mr. Ayers will continue to serve as a member of the Company’s Board of Directors (the “ Board ”) but will no longer serve as its Chairman. In connection with the foregoing, on October 23, 2019, Mr. Ayers and the Company entered into a Mutual Separation Agreement (the “ Mutual Separation Agreement ”) and a Senior Advisory Agreement (the “ Senior Advisory Agreement ”), as more fully described below.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.